Aquestive Therapeutics, Inc. filed a Current Report on Form 8-K dated November 16, 2026, disclosing information presented at the Jefferies Global Healthcare Conference held on the same date. The company provided an investor presentation to institutional investors, analysts, and others, which is attached as Exhibit 99.1 to the filing.

The presentation focused on the regulatory status of Anaphylm (AQST-109), a sublingual film intended for the emergency treatment of severe allergic reactions. The company stated that Anaphylm is an investigational product candidate that has not been approved by the FDA. The proprietary name "Anaphylm" has been conditionally accepted by the FDA, with final acceptance conditioned upon the product candidate receiving FDA approval.

The filing outlines the company's strategy for addressing a Complete Response Letter (CRL) received from the FDA on January 30, 2026. Management indicated that the company is pursuing a Class 2 resubmission of the New Drug Application (NDA) for Anaphylm. The company referenced a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027, for this resubmission.

The company also discussed its broader commercialization strategy for Anaphylm, should it receive approval. This includes plans for a sales force, prescriber targeting, patient support programs, and payer engagement. Additionally, the company outlined its AdrenaVerse pipeline, which includes the epinephrine prodrug candidate AQST-108, currently in development as a topical gel.

The filing includes a standard set of forward-looking statements regarding the timing of regulatory approvals, the potential for market acceptance, the company's liquidity, and the execution of its commercialization plans. These statements are subject to risks and uncertainties, including the possibility that the FDA may disagree with the company's interpretation of study results or request additional information.